Copyright
©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Crit Care Med. Feb 4, 2014; 3(1): 34-41
Published online Feb 4, 2014. doi: 10.5492/wjccm.v3.i1.34
Published online Feb 4, 2014. doi: 10.5492/wjccm.v3.i1.34
Ulinastatin for acute lung injury and acute respiratory distress syndrome: A systematic review and meta-analysis
Yu-Xin Leng, Shu-Guang Yang, Xi Zhu, Gai-Qi Yao, Department of Intensive Care Unit, Peking University Third Hospital, Beijing 100191, China
Ya-Han Song, Library of Peking University Third Hospital, Beijing 100191, China
Author contributions: Leng YX and Yang SG contributed to literature search and study selection; Leng YX and Song YH contributed to data extraction, analysis and interpretation; Yao GQ, Zhu X and Yao GQ contributed to study conception and design; Leng YX drafted the article; Yao GQ revised the article critically for important intellectual content.
Correspondence to: Gai-Qi Yao, MD, PhD, Associate Professor, Department of Intensive Care Unit, Peking University Third Hospital, A 49 North Garden Rd., Haidian District, Beijing 100191, China. yaogaiqi@yeah.net
Telephone: +86-10-82267280 Fax: +86-10-82267281
Received: June 5, 2013
Revised: October 5, 2013
Accepted: November 2, 2013
Published online: February 4, 2014
Revised: October 5, 2013
Accepted: November 2, 2013
Published online: February 4, 2014
Core Tip
Core tip: Currently, many studies highlight the advantages of ulinastatin in lung protection, which is likely because acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) share a common pathogenesis with sepsis. We tried to provide more specific evidence on this practice by performing a meta-analysis. In our study (29 clinical trials included), we found that though all the studies were of low quality, ulinastatin might improve oxygenation and mortality and be truly effective in patients with ALI/ARDS.